Columnist Desiree Lama finds herself having to argue that a medicine that she has been taking for migraines for years is still needed.

The primary difference between the Wegovy pill and the injection is how you take them and how often. The Wegovy pill is a daily tablet you swallow, while the Wegovy injection is a once-weekly shot you ...

New hypertension treatments may reduce dosage to two injections annually instead of daily pills Zilebesiran uses siRNA to lower blood pressure by targeting angiotensinogen production in the liver Long ...

After Lundbeck scrapped one portion of its trial, the company's intravenous monoclonal antibody has met the main goal of a phase 2b migraine prevention study, with multiple doses of the experimental ...

Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade “I just felt slow: I want to be able to do anything my kids want to do and not have weight ...

Earnings call Organon reported 2025 revenue of $6.2B (down 3% YoY) and adjusted EBITDA of $1.9B (flat YoY), maintaining margins despite gross margin compression. 2026 guidance projects flat revenue ...

Hello, and welcome to the Organon Fourth Quarter and Full Year 2025 Earnings Call and webcast. [Operator Instructions]. I would now like to turn the conference over to Jennifer Halchak, Vice President ...

Organon & Co reported its fourth-quarter 2025 earnings, revealing a significant shortfall in earnings per share (EPS) compared to forecasts. The company posted an EPS of $0.63, falling short of the ...

Established Brands, which represents the largest portion of Organon’s business at $3.69 billion in 2025 revenue, faced headwinds from loss of exclusivity for Atozet and challenges in the respiratory ...

Jennifer Halchak: Thank you, operator. Good morning, everyone. With me today are Joe Morrissey, Organon's Interim Chief Executive Officer; and Matt Walsh, our Chief Financial Officer; Carrie Cox, ...

(1) Excludes accelerated depreciation included in one-time costs. (2) Spin-related costs reflect certain costs incurred in connection with activities taken to separate Organon from Merck & Co., Inc., ...

Leqvio (inclisiran) may cause injection site reactions, including bruising, pain, discoloration, itchiness, and a burning or prickling sensation at the injection site. In addition to injection site ...